Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.

@article{George2014Phase2T,
  title={Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.},
  author={Suzanne George and Yang Feng and Judith B. Manola and Marisa R. Nucci and James E. Butrynski and Jeffrey A. Morgan and Nikhil Himmatsinh Ramaiya and Richard Hong-Hui Quek and Richard T. Penson and Andrew J. Wagner and David Harmon and George Daniel Demetri and Carolyn Krasner},
  journal={Cancer},
  year={2014},
  volume={120 5},
  pages={738-43}
}
BACKGROUND Advanced uterine leiomyosarcoma (ULMS) is an incurable disease. A significant percentage of cases of ULMS express estrogen and/or progesterone receptors (ER and/or PR). To the authors' knowledge, the role of estrogen suppression in disease management is not known. METHODS The authors performed a single-arm phase 2 study of the aromatase inhibitor letrozole at a dose of 2.5 mg daily in patients with unresectable ULMS with ER and/or PR expression confirmed by immunohistochemistry… CONTINUE READING